- Market Realist•19 hours ago
On May 27, 2016, AbbVie and Biogen’s Zinbryta was approved by the FDA as a therapy for adults suffering from relapsing forms of MS (multiple sclerosis).
- Market Realist•20 hours ago
AbbVie (ABBV) expects to file a biologics license application for Rova-T as a third-line therapy for small cell lung cancer (or SCLC) in 2017.
- 24/7 Wall St.•21 hours ago
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
AbbVie Inc. (ABBV)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||63.74 x 400|
|Ask||65.77 x 100|
|Day's Range||64.27 - 65.43|
|52wk Range||45.45 - 68.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||18.67|
|Avg Vol (3m)||7,974,635|
|Dividend & Yield||2.28 (3.50%)|